Theravance Biopharma
TBPH
83 hedge funds and large institutions have $425M invested in Theravance Biopharma in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 12 closing their positions.
4,700% more call options, than puts
Call options by funds: $96K | Put options by funds: $2K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
89% more capital invested
Capital invested by funds: $226M → $425M (+$200M)
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
0% more funds holding
Funds holding: 83 → 83 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$74.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 4 |
GAM
Gotham Asset Management
New York
|
+$1.1M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$674K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$6M |
| 2 |
CC
Clearline Capital
New York
|
-$5.68M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.03M |
| 4 |
RP
Reinhart Partners
Mequon,
Wisconsin
|
-$1.8M |
| 5 |
RA
Royce & Associates
New York
|
-$1.67M |
TBPH Hedge Fund Activity: Q4 2015 in Review
83 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2015, worth a combined $425M — up 89% from $226M a quarter earlier.
Fund positioning in TBPH was balanced in Q4 2015: 12 funds opened new positions, 12 closed out, 32 added to existing stakes and 21 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $74.6M. The largest seller was Norges Bank, cutting an estimated $6M.
- 83 institutional investors held Theravance Biopharma (TBPH) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $425M of Theravance Biopharma stock for Q4 2015, up 89% quarter-over-quarter.
- 12 funds opened new Theravance Biopharma positions in Q4 2015 and 12 closed out, a net change of 0 holders.
- The largest Theravance Biopharma buyer in Q4 2015 was Woodford Investment Management, an estimated $74.6M added.
- The largest Theravance Biopharma seller in Q4 2015 was Norges Bank, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2015.